参一胶囊联合FOLFOX4方案治疗晚期大肠癌35例分析  

Ginsenoside Rg3 capsules combined with FOLFOX4 regimen for treatment of advanced colon cancer:a report of 35 cases

作　　者：曾冬香[1] 凌扬[1] 杨全良[1] 孙毅[1] 

机构地区：[1]苏州大学附属常州肿瘤医院肿瘤内科,江苏常州213001

出　　处：《蚌埠医学院学报》2009年第12期1092-1094,共3页Journal of Bengbu Medical College

基　　金：江苏省常州市卫生局指导性科技项目(WZ200726)

摘　　要：目的:观察参一胶囊联合FOLFOX4方案化疗治疗晚期大肠癌的疗效、毒副反应、细胞免疫功能的变化。方法:将67例晚期大肠癌患者按照治疗方案不同随机分为两组:A组单纯接受FOLFOX4方案化疗,B组在化疗同时联合应用参一胶囊。结果:A、B两组近期客观疗效(完全缓解+部分缓解)分别为40.6%和45.7%,差异无统计学意义(P>0.05),B组血液学毒性发生率低于A组(P<0.05),在生活质量和免疫功能改善方面两组差异均有统计学意义(P<0.05～P<0.01)。结论:参一胶囊可减轻化疗毒副反应,有利于改善患者生活质量和免疫功能。Objective：To observe the effect,adverse reaction and cytoimmunity function of ginsenoside Rg3 capsules combined with FOLFOX4 regimen in treatment of advanced colon cancer.Methods：Sixty-seven patients were randomly divided into two groups.Group A（32 cases）received FOLFOX4 regimen only,and Group B（35 cases）were treated with ginsenoside Rg3 capsules plus FOLFOX4 regimen.Results：The response rate was 40.6% in group A and 45.7% in group B（P〉0.05）.A lower response rate of leucopenia occurred in group B compared with that in group A（P〈0.05-P〈0.01）.The difference was significant in the elevation of T lymphocyte subset and life quality between the two groups.Conclusions：Ginsenoside Rg3 capsules can decrease the side effects of chemotherapy and improve the immunity and life quality of the patients with advanced colon cancer

关 键 词：大肠肿瘤 参一胶囊 FOLFOX4方案 

分 类 号：R735.34[医药卫生—肿瘤]